-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompileKe Ke
On April 12, AstraZeneca announced that its diabetes drug Farxiga (dapagliflozin) failed to reach the end point in a phase three study.
According to AstraZeneca, the company conducted this research in cooperation with St.
AstraZeneca pointed out in the announcement that in the 30-day Phase III clinical study DARE-19, Farxiga did not reach statistical significance.
However, the safety and tolerability of Farxiga are still consistent with the accepted safety of the drug.
Farxiga is a "first-in-class" oral SGLT2 inhibitor, once a day.
The patients participating in the study had a history of heart, kidney, and metabolic comorbidities, including hypertension, heart failure, chronic kidney disease, and atherosclerotic cardiovascular disease.
AstraZeneca did not provide all the data of the study in its announcement on the 12th.
Farxiga is certainly not the only drug that has failed clinical studies in response to the COVID-19 pandemic.
The DARE-19 study provides important data on the potential benefits and risks of using SGLT2 inhibitors to treat COVID-19 hospitalized patients.
One question is, will SGLT2 inhibitors (such as Farxiga) increase the risk of rare complications in COVID-19 diabetic patients? In January of this year, a study at Brigham and Women's Hospital in Massachusetts found that five COVID-19 patients taking SGLT2 inhibitors had rare side effects.
Reference source:
1.
2.
